Bruker Corporation (BRKRP) vs Vaxcyte, Inc. (PCVX)
A side-by-side comparison of Bruker Corporation and Vaxcyte, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BRKRP
Bruker Corporation
$445.04HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
PCVX
Vaxcyte, Inc.
$66.70HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — BRKRP vs PCVX
growth of $100 · dividends reinvested · last 1yBRKRP +94.8% (+94.8%/yr)PCVX +130.0% (+130.0%/yr)PCVX compounded faster over this window
BRKRP PCVX
BRKRP vs PCVX: by the numbers
- •PCVX is the larger company ($9.63B vs $8.93B market cap).
- •Both run net losses; PCVX's is the smaller (0.00% vs -2.03% net margin).
- •BRKRP pays a dividend (3.35% yield), while PCVX has no payments in the available dividend history.
Metrics side by side
Valuation
| Metric | BRKRP | PCVX |
|---|---|---|
| Forward P/E | 209.72 | N/A |
| P/S ratio | 2.55 | N/A |
| P/B ratio | 3.72 | 3.49 |
| EV / EBITDA | 29.89 | N/A |
| FCF yield | 1.05% | N/A |
Profitability
| Metric | BRKRP | PCVX |
|---|---|---|
| Gross margin | 46.69% | 0.00% |
| Operating margin | 3.61% | 0.00% |
| Net margin | -2.03% | 0.00% |
| ROE | -2.97% | -38.59% |
| ROIC | 2.56% | -40.65% |
Dividends
| Metric | BRKRP | PCVX |
|---|---|---|
| Dividend yield | 3.35% | N/A |
Growth (annualized)
| Metric | BRKRP | PCVX |
|---|---|---|
| Revenue CAGR (5Y) | 9.10% | N/A |
| FCF CAGR (5Y) | -21.33% | N/A |
| Total return CAGR (5Y) | N/A | 25.08% |
Frequently asked
- Does BRKRP or PCVX pay a bigger dividend?
- BRKRP pays a dividend (3.35% yield), while PCVX has no payments in the available dividend history.
Go deeper
Dig into the metrics
Bruker dividend yieldBruker ROEVaxcyte ROEBruker operating marginVaxcyte operating marginBruker revenue growthVaxcyte revenue growthBruker free cash flowVaxcyte free cash flow
Bruker & Vaxcyte appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.